This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Green, Inc. Strengthens Board Of Directors And Management Team And Receives Advance In Funds From Chairman And CEO To Support Company's Growth

TALLAHASSEE, Fla., Jan. 16, 2013 /PRNewswire/ --   Global Green, Inc. (OTCBB: GOGC) today announced that Konky Sotomayor, DVM, the developer of Salmogenics, has been appointed to the Board of Directors and to the position within the Company of Chief Scientist and Vice President – R&D.

Global Green also announced that Dr. Mehran Ghazvini, Chairman and CEO, has advanced the Company $300,000 to support the Company's growth.  This amount will be paid back to Dr. Ghazvini at a future date in preferred shares, cash or a combination of both.

Dr. Sotomayor graduated with honors as a Doctor in Veterinary Medicine and Zootechny in the Veterinary Medicine Faculty from the State University of Guayaquil in Ecuador. He attended the prestigious Lantanisbruk Universitet in Uppsala, Sweden, renowned for their International Science Program. The program assists countries in strengthening their domestic research capacity within the chemical, physical and the mathematical sciences.

Dr. Sotomayor has worked in private laboratory-managing research and development positions since 1979 including being a principal of Nutritional Health Institute Laboratories, LLC ("NHIL").  NHIL is Global Green's research affiliate and majority shareholder. He has extensive experience in isolation of infectious disease agents and manufacturing of the corresponding vaccines.

Dr. Ghazvini stated, "Dr. Sotomayor, the developer of the Salmogenics, the Company's patented Salmonella vaccine, is a perfect addition to our Board of Directors.  His character, strong background and an extensive track record in animal infectious disease research and laboratory diagnostics makes him an important asset.  As we execute our core strategy and work to build a pipeline of high value drug discovery and development programs to deliver tangible results, Dr. Sotomayor's leadership as Chief Scientist and VP – R&D will be critical."

The Salmogenics vaccine is in its last stages of testing and trials before the final United States Department of Agriculture/Food Safety and Inspection Service ("USDA") approval for its commercial application.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,061.69 +23.72 0.13%
S&P 500 2,109.69 +0.77 0.04%
NASDAQ 5,059.9660 -0.28 -0.01%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs